Literature DB >> 26387543

Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.

C Chalermrujinanant1, W Michowski2, G Sittithumcharee1, F Esashi3, S Jirawatnotai1,2,4.   

Abstract

BRCA2 has an important role in the maintenance of genome stability by interacting with RAD51 recombinase through its C-terminal domain. This interaction is abrogated by cyclin A-CDK2-mediated phosphorylation of BRCA2 at serine 3291 (Ser3291). Recently, we showed that cyclin D1 facilitates RAD51 recruitment to BRCA2-containing DNA repair foci, and that downregulation of cyclin D1 leads to inefficient homologous-mediated DNA repair. Here, we demonstrate that cyclin D1, via amino acids 20-90, interacts with the C-terminal domain of BRCA2, and that this interaction is increased in response to DNA damage. Interestingly, CDK4-cyclin D1 does not phosphorylate Ser3291. Instead, cyclin D1 bars cyclin A from the C-terminus of BRCA2, prevents cyclin A-CDK2-dependent Ser3291 phosphorylation and facilitates RAD51 binding to the C-terminal domain of BRCA2. These findings indicate that the interplay between cyclin D1 and other cyclins such as cyclin A regulates DNA integrity through RAD51 interaction with the BRCA2 C-terminal domain.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26387543      PMCID: PMC6538526          DOI: 10.1038/onc.2015.354

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  60 in total

1.  Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations.

Authors:  B H Spain; C J Larson; L S Shihabuddin; F H Gage; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Rapid destruction of human Cdc25A in response to DNA damage.

Authors:  N Mailand; J Falck; C Lukas; R G Syljuâsen; M Welcker; J Bartek; J Lukas
Journal:  Science       Date:  2000-05-26       Impact factor: 47.728

3.  RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein.

Authors:  R Mizuta; J M LaSalle; H L Cheng; A Shinohara; H Ogawa; N Copeland; N A Jenkins; M Lalande; F W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

4.  A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.

Authors:  Siwanon Jirawatnotai; Yiduo Hu; Wojciech Michowski; Joshua E Elias; Lisa Becks; Frederic Bienvenu; Agnieszka Zagozdzon; Tapasree Goswami; Yaoyu E Wang; Alan B Clark; Thomas A Kunkel; Tanja van Harn; Bing Xia; Mick Correll; John Quackenbush; David M Livingston; Steven P Gygi; Piotr Sicinski
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

5.  BRCA2 mutations in primary breast and ovarian cancers.

Authors:  J M Lancaster; R Wooster; J Mangion; C M Phelan; C Cochran; C Gumbs; S Seal; R Barfoot; N Collins; G Bignell; S Patel; R Hamoudi; C Larsson; R W Wiseman; A Berchuck; J D Iglehart; J R Marks; A Ashworth; M R Stratton; P A Futreal
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

6.  Purified human BRCA2 stimulates RAD51-mediated recombination.

Authors:  Ryan B Jensen; Aura Carreira; Stephen C Kowalczykowski
Journal:  Nature       Date:  2010-10-07       Impact factor: 49.962

7.  Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats.

Authors:  Owen Richard Davies; Luca Pellegrini
Journal:  Nat Struct Mol Biol       Date:  2007-06       Impact factor: 15.369

8.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.

Authors:  C Gillett; V Fantl; R Smith; C Fisher; J Bartek; C Dickson; D Barnes; G Peters
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

9.  Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis.

Authors:  J Bartkova; J Lukas; M Strauss; J Bartek
Journal:  Oncogene       Date:  1995-02-16       Impact factor: 9.867

10.  CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair.

Authors:  Fumiko Esashi; Nicole Christ; Julian Gannon; Yilun Liu; Tim Hunt; Maria Jasin; Stephen C West
Journal:  Nature       Date:  2005-03-31       Impact factor: 49.962

View more
  8 in total

1.  Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers.

Authors:  Josephine Hai; Shengwu Liu; Lauren Bufe; Khanh Do; Ting Chen; Xiaoen Wang; Christine Ng; Shuai Li; Ming-Sound Tsao; Geoffrey I Shapiro; Kwok-Kin Wong
Journal:  Clin Cancer Res       Date:  2017-08-18       Impact factor: 12.531

Review 2.  Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.

Authors:  Fatemeh Sadeghi; Marzieh Asgari; Mojdeh Matloubi; Maral Ranjbar; Nahid Karkhaneh Yousefi; Tahereh Azari; Majid Zaki-Dizaji
Journal:  Biol Proced Online       Date:  2020-10-01       Impact factor: 3.244

Review 3.  Guardians of the Genome: BRCA2 and Its Partners.

Authors:  Hang Phuong Le; Wolf-Dietrich Heyer; Jie Liu
Journal:  Genes (Basel)       Date:  2021-08-10       Impact factor: 4.141

4.  Jungermannenone A and B induce ROS- and cell cycle-dependent apoptosis in prostate cancer cells in vitro.

Authors:  Yan-Xia Guo; Zhao-Min Lin; Mei-Juan Wang; Yi-Wen Dong; Huan-Min Niu; Charles Yf Young; Hong-Xiang Lou; Hui-Qing Yuan
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

Review 5.  The double dealing of cyclin D1.

Authors:  Guergana Tchakarska; Brigitte Sola
Journal:  Cell Cycle       Date:  2019-12-29       Impact factor: 4.534

6.  Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines.

Authors:  Frank Ziemann; Steve Seltzsam; Kristin Dreffke; Stefanie Preising; Andrea Arenz; Florentine S B Subtil; Thorsten Rieckmann; Rita Engenhart-Cabillic; Ekkehard Dikomey; Andrea Wittig
Journal:  Oncotarget       Date:  2017-10-24

7.  Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers.

Authors:  Yuqiu Ge; Yunyan Wang; Wei Shao; Jing Jin; Mulong Du; Gaoxiang Ma; Haiyan Chu; Meilin Wang; Zhengdong Zhang
Journal:  Sci Rep       Date:  2016-09-16       Impact factor: 4.379

Review 8.  The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target.

Authors:  Ziyi Wang; Renxiang Jia; Linlin Wang; Qiwei Yang; Xiaohai Hu; Qiang Fu; Xinyu Zhang; Wenya Li; Yi Ren
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.